Achaogen Revenue and Competitors
Estimated Revenue & Valuation
- Achaogen's estimated annual revenue is currently $1.6M per year.
- Achaogen's estimated revenue per employee is $77,500
- Achaogen's total funding is $178.7M.
Employee Data
- Achaogen has 21 Employees.
- Achaogen grew their employee count by -32% last year.
Achaogen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Achaogen?
Before the 1930s, even minor infections — strep throat, for example — were life-threatening. The introduction of antibiotics changed that. Not only did these drugs dramatically increase the length and quality of human life, but they also enabled practices now considered to be central to modern medicine (e.g., surgery). The emergence of drug-resistant bacteria, however, threatens to undo these dramatic medical advances, potentially restoring common bacteria to their historical role as a significant threat to human health. Achaogen is pursuing unique strategies to combat these drug-resistant pathogens. Our scientific strategy is without precedent and represents a fundamentally new approach to address this growing healthcare crisis.
keywords:Biotechnology, Healthcare
$178.7M
Total Funding
21
Number of Employees
$1.6M
Revenue (est)
-32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Achaogen News
Achaogen Inc; Astrazeneca Plc; Meiji Seika Pharma Co Ltd; Merck & Co Inc; Merlion Pharmaceuticals Pte Ltd; The Medicines Company; Zavante...
Achaogen Inc, Novartis AG, Biolytics Pharma, LegoChem Biosciences Inc, Inhibrx LP, ContraFect Corp, AmpliPhi Biosciences Corp,...
A June 2019 auction ended with Cipla submitting the high bid for the global rights to Achaogen's plazomicin antibiotic drug. The Chinese rights...
Achaogen’s journey from promise to penury illustrates the Herculean task the biopharma industry faces: Fulfill a growing need for antibiotics while facing economic realities that make doing so unprofitable. As is apparent from the proliferation of apocalyptic stories about a future “post-antibi ...
Top VC recipients of 2010: As we (kind of) near the halfway point of 2010, peHUB runs down the top venture capital recipients so far. Alas, the healthcare industry has but one apperance and it’s at No. 10. Achaogen, a San Francisco-based developer of antibiotics to treat life-threatening, multid ...
Other Companies in South San Francisco
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.3M | 21 | -19% | N/A |
#2 | $1.7M | 22 | -80% | $187M |
#3 | $3.6M | 23 | 0% | N/A |
#4 | $3.6M | 23 | 5% | N/A |
#5 | $3.7M | 24 | 0% | N/A |